Cadrenal Therapeutics Inc CVKD

NAS: CVKD | ISIN: US1276361086 17/05/2024

0,411 USD (-4,44%)

(-4,44%) 17/05/2024

Toon enkel gratis nieuws

9 mei 2024 · Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update · Persbericht

11 april 2024 · Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 · Persbericht

9 april 2024 · Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts · Persbericht

11 maart 2024 · Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update · Persbericht

26 februari 2024 · Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference · Persbericht

8 februari 2024 · Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial · Persbericht

31 januari 2024 · Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions · Persbericht

24 januari 2024 · Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 · Persbericht

4 januari 2024 · Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe